Overview

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
Phase:
Phase 3
Details
Lead Sponsor:
AB Science